Janus Kinase Inhibitor

Patients with alopecia areata who were treated with ritlecitinib or brepocitinib had significant downregulation of immune biomarkers, according to a biopsy sub-study.

Most patients with rheumatoid arthritis were involved in conversations about treatment decisions with their rheumatologist, according results of a multinational European survey presented at ACR Convergence 2021.

A 2019 European Medicines Agency warning that tofacitinib could increase risk for venous thromboembolism in patients with rheumatoid arthritis did not affect characteristics of patients starting the drug since then, according to a study.

Calprotectin was found to be related to ultrasound synovitis scores in patients with rheumatoid arthritis treated with interleukin-6 inhibitors and janus kinase inhibitors, according to a poster presented at ACR Convergence 2021.

Patients with rheumatoid arthritis who fail their first JAK inhibitor can achieve success with either “cycling” to another JAK inhibitor or switching to a biologic disease-modifying antirheumatic drug, according to data presented at ACR Convergence 2021.

Nothing is easy in the management of COVID-19. Similarly, nothing is easy in managing immunocompromised patients. Marry the two and the challenges more than double.

Janus kinase inhibitors are associated with numerical, but not statistically significant, risks for adverse cardiovascular events and malignancy, according to a presenter at the 2021 Congress of Clinical Rheumatology-West.

A recent safety review of janus kinase inhibitors revealed that the medications were linked to an increased risk for serious heart-related events, cancer, blood clots and death.

There is no increased risk for cancer overall associated with the long-term use of TNF inhibitors for rheumatoid arthritis, according to data published in Rheumatology.

The FDA has called for additional warning labels on janus kinase inhibitors after a safety review found this class of medications was associated with an excess risk for serious heart-related events, cancer, blood clots and death.